Efficiency and Safety of Inhaled Amphotericin B Lipid Complex (Abelcet) in the Prophylaxis of Invasive Fungal Infections Following Lung Transplantation

Transplantation Proceedings

Volumn 40, Issue 9, 2008, Pages 3090-3093

  Borro, J M ^a   Sole A ^b   de la Torre, M ^a   Pastor, A ^b   Fernandez, R ^a   Saura, A ^b   Delgado, M ^a   Monte, E ^b   Gonzalez, D ^a  

^a HOSPITAL JUAN CANALEJO   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; FLUCONAZOLE;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MYCOSIS; NAUSEA AND VOMITING; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; SCHOOL CHILD; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CHILD; FEMALE; FLUCONAZOLE; HUMANS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; MYCOSES; NAUSEA; RETROSPECTIVE STUDIES; RISK FACTORS; SAFETY; VOMITING; YOUNG ADULT;

EID: 55749099145     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.09.020     Document Type: Article

References (24)

1. Singh N., and Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J Heart Lung Transplant 22 (2003) 258
2. Sole A., Morant P., Salavert M., et al. Aspergillus infections in lung transplant recipients: risk factors and outcome. Clin Microbiol Infect 11 (2005) 359
3. Segal B.H., and Walsh T.J. Current approaches to diagnosis and treatment of invasive Aspergillosis. Am J Respir Crit Care Med 173 (2006) 707
4. Kotloff R.M., Ahya V.N., and Crawford S.W. Pulmonary complications of solid organ and hematopoietic stem cell transplantation. Am J Respir Crit Care Med 170 (2004) 22
5. Marik P.E. Fungal infections in solid organ transplantation. Expert Opin Pharmacother 7 (2006) 297
6. San Juan Garrido R., Aguado J.M., Lumbreras C., et al. Incidence, clinical characteristics and risk factors of late infection in solid organ transplant recipients. data from the RESITRA study group. Am J Transplant 7 (2007) 964
7. Covarrubias M.B., and Milstone A.B. An overview of fungal prophylaxis in lung transplantation. Curr Opin Organ Transplant 10 (2005) 272
8. Magill S.S. Antifungal prophylaxis in transplant recipients: where do we go from here?. Transpl Infect Dis 8 (2006) 187
9. Husain S., Paterson D.K.L., Studerd S., et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant 6 (2006) 3008
10. Drew R. Potential role of aerosolized amphotericin B formulations in the prevention and adjunctive treatment of invasive fungal infections. Int J Antimicrob Agents 27 (2006) S36
11. Knechtel S., and Klepser M. Safety of aerosolized amphotericin B. Expert Opin Drug Saf 6 (2007) 523
12. Reichenspurner H., Gamberg P., Nitschke M., et al. Significant reduction in the number of fungal infections after lung, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis. Transplant Proc 26 (1997) 627
13. Calvo V., Borro J.M., Morales P., et al. Antifungal prophylaxis during the early postoperative period of lung transplantation. Valencia Lung Transplant Group. Chest 115 (1999) 1301
14. Monforte V., Roman A., Gavalda J., et al. Nebulized amphotericin B concentration and distribution in the respiratory tract of lung-transplanted patients. Transplantation 75 (2003) 1571
15. Palmer S.M., Drew H., Whitehouse J.D., et al. Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation 72 (2001) 545
16. Drew H., Dodds A.E., Benjamin Jr. D.K., et al. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 77 (2004) 232
17. Monforte V., Roman A., Gavalda J., et al. Nebulized liposomal Amphotericin B (n-LAB) prophylaxis for Aspergillus infection in lung transplantation: pharmacokinetics, safety and efficacy. J Heart Lung Transplant 24 (2005) s108
18. Lowry C.M., Marty F.M., Vargas S.O., et al. Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study. Transpl Infect Dis 9 (2007) 121
19. Corcoran T.E., Venkataramanan R., Mihel K.M., et al. Aerosol deposition of lipid complex amphotericin-B (Abelcet) in lung transplant recipients. Am J Transplant 6 (2006) 2765
20. Ascioglu S., Rex J.H., Pauw B., et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34 (2002) 1648
21. Gryn J., Goldberg J., Johnson E., et al. The toxicity of daily inhaled amphotericin B. Am J Clin Oncol 16 (1993) 43
22. Abe M., Kondo K., Fujino S., et al. Lipoid pneumonia combined with pulmonary nocardiosis caused by inhalation of amphotericin-B after renal transplantation. Nihon Kyobu Shikkan Gakkai Zasshi Japanese 34 (1996) 737
23. Allen S.D., Sorensen K.N., Nejdl M.J., et al. Efficacy of aerosolized liposomal amphotericin B (AmBisome) as a prophylactic treatment in an immune compromised murine model of pulmonary aspergillosis. J Control Release 28 (1994) 348
24. Cicogna C.E., White M.H., Bernard E.M., et al. Efficacy of prophylactic aerosol amphotericin B lipid complex in a rat model of pulmonary aspergillosis. Antimicrob Agents Chemother 41 (1997) 259